|
|
Science Sparks @ ACTREC
|
27 March 2023 |
Vol. No. 12; Issue No. 571 |
|
Publications
|
1. Patil A, Diwakar H, Sawant J, Kurian N, Yadav S, Rane S, Bameta T, Sethi A (2023). Efficient quality control of whole slide pathology images with human-in-the-loop training. Journal of Pathology Informatics.
2. Mohanty SK, Wadasadawala T, Sen S, Khan PK (2023). Socio-economic variations of breast cancer treatment and discontinuation: a study from a public tertiary cancer hospital in Mumbai, India. BMC Womens Health. 23(1):113.
3. Krishnatry R, Maitre P, Kumar A, Telkhade T, Bakshi G, Prakash G, Pal M, Joshi A, Menon S, Murthy V (2023). Utilising alternative cystoscopic schedules to minimise cost and patient burden after trimodality therapy for muscle-invasive bladder cancer. Cancer Medicine.
|
|
|
|
Legends of Science
|
|
Hiriyakkanavar Ila
Hiriyakkanavar Ila received her PhD from the Indian Institute of Technology, Kanpur, in 1968. Her research topic was heterocyclic chemistry. Her contribution has been designing and developing new efficient methodologies for a wide range of substituted and fused five and six-membered heterocycles utilizing organosulfur synthons, such as polarized ketene dithioacetals and the corresponding N, S- acetals derived from them, as versatile building blocks. She received the AV Rama Rao Prize (2001) and the CRSI silver medal (2002). She is a Fellow of the Indian Academy of Sciences, Bangalore (1991) and Fellow of the Indian National Academy, New Delhi (2002).
|
|
|
|
Indira Nath
Indira Nath received her MD in Pathology from All India Institute of Medical Sciences, in 1969. She made pioneering contributions in the field of cellular immunity in human leprosy and the discovery of LSR2 gene in the leprosy bacillus. She was the founder Head of the Department of Biotechnology at the All India Institute of Medical Sciences. She was the Member of the Scientific Advisory Committee of the Union Cabinet, Government of India. She received Shanti Swarup Bhatnagar Award (1983), Padma Shri (1999) and Cochrane Research Award (1999).
|
|
|
|
|
Do You Know?
In 2017, an early stage clinical trial provided the first data suggesting that the PD-1-targeted immunotherapy nivolumab(Opdivo) may be benefical in advanced hepatocellular carcinoma.
|
|
|
|
2023 Advanced Centre for Treatment, Research and Education in Cancer (ACTREC)
|
|